articlesMay 25, 2026·5 min read

GLP-1s Now FDA-Approved for Fatty Liver Disease

Semaglutide and tirzepatide both FDA-approved for MASH. 63% resolution rate, fibrosis reversal in trials. What the data shows and sourcing options.

Save

Translucent human liver glowing with blue-purple healing energy as GLP-1 molecules dock onto its surface on dark navy background

Both semaglutide and tirzepatide are now FDA-approved for metabolic dysfunction-associated steatohepatitis (MASH) — the severe, inflammatory form of fatty liver disease that affects an estimated 6-8 million Americans with significant fibrosis. Semaglutide's approval came in August 2025 via the Phase 3 ESSENCE trial; tirzepatide followed in early 2026 on breakthrough therapy designation and the SYNERGY-NASH data. The 2026 EASO guideline update now positions both drugs in its liver treatment algorithm for the first time.

This is the biggest expansion of GLP-1 indications beyond weight loss and diabetes since semaglutide picked up the cardiovascular (SELECT trial) and heart failure (STEP-HFpEF) labels. For the estimated 80 million Americans with some form of fatty liver disease, there are now two on-label GLP-1 options where there were zero three years ago.

The Trial Data: Resolution Rates and Fibrosis

Semaglutide — ESSENCE Trial (Phase 3)

The ESSENCE trial randomized adults with biopsy-confirmed non-cirrhotic MASH and stage F2-F3 liver fibrosis to semaglutide 2.4 mg weekly or placebo. Part 1 results at 72 weeks:

  • MASH resolution without worsening fibrosis: 62.9% on semaglutide vs. 34.3% on placebo
  • Fibrosis improvement without worsening MASH: 37% on semaglutide vs. 22% on placebo
  • Liver fat reduction: significant decreases in hepatic steatosis measured by imaging within the first 12 weeks

The trial enrolled patients regardless of diabetes status — both Type 2 diabetic and non-diabetic populations benefited. Semaglutide received accelerated approval with Part 2 confirmatory data expected by 2029.

Tirzepatide — SYNERGY-NASH Trial (Phase 2)

The SYNERGY-NASH trial tested three tirzepatide doses in adults with biopsy-confirmed MASH and stage F2-F3 fibrosis. Results at 52 weeks:

  • MASH resolution (5 mg): 51.8% vs. 13.2% placebo
  • MASH resolution (10 mg): 62.8% vs. 13.2% placebo
  • MASH resolution (15 mg): 73.3% vs. 13.2% placebo
  • Fibrosis improvement (at least one stage): ~51% at highest dose

Tirzepatide's dual GIP/GLP-1 mechanism appears to reduce liver lipid uptake through CD36 and OBP2A pathways, potentially explaining the dose-response pattern above what weight loss alone would predict. A Phase 3 SYNERGY-OUTCOMES trial launched in late 2025 and targets completion in 2032.

Side-by-side liver cross-sections showing fatty deposits resolving into healthy tissue with blue-purple energy on dark background

2026 EASO Guidelines: Where Each Drug Fits

The European Association for the Study of Obesity published its updated pharmacotherapy framework in May 2026 (Nature Medicine). The previous version treated liver disease as a single domain. The 2026 update splits the MASH algorithm into two distinct therapeutic goals:

For MASH resolution: Both semaglutide and tirzepatide are recommended. The ESSENCE dataset is the most mature for the fibrotic MASH population, but tirzepatide's SYNERGY-NASH resolution rates are compelling.

For liver fibrosis improvement: Only semaglutide currently appears in the algorithm. Tirzepatide's fibrosis data comes from secondary endpoints in SYNERGY-NASH rather than a powered Phase 3 fibrosis trial. This gap will likely close when SYNERGY-OUTCOMES reports.

The clinical takeaway: if fibrosis reduction is the primary goal, the evidence currently favors semaglutide. If MASH resolution is the target (and fibrosis is F2, not F3), tirzepatide's higher resolution rates at the top dose give it an edge.

Real-World Evidence Reinforces the Trials

Beyond the controlled trials, real-world data is stacking up. A target trial emulation using electronic health records found that semaglutide and tirzepatide reduced the risk of major liver outcomes in people with Type 2 diabetes by 28% and 39%, respectively, compared to other glucose-lowering agents. Liver enzyme normalization (ALT, AST) appears within 24-36 weeks in clinical practice — often before patients have hit their weight-loss plateau.

A semaglutide dose-duration meta-analysis across randomized trials confirmed that liver steatosis improves in a dose-dependent manner, with 2.4 mg weekly producing the most consistent reductions.

What This Means If You Have Fatty Liver Disease

MASH has historically been a diagnosis with minimal treatment options — lifestyle modification and resmetirom (approved in 2024) were essentially it. Two FDA-approved GLP-1 options change the calculus:

  1. Prescription route: Both semaglutide and tirzepatide are available by prescription for the MASH indication specifically. This means insurance coverage conversations now have an FDA-approved indication to support prior authorization.

  2. Compounding route: 503A pharmacies can prepare both with a valid prescription. The FDA's April 2026 proposal to exclude semaglutide and tirzepatide from the 503B outsourcing facility bulk drug substances list is in public comment through June 30, 2026, but hasn't been finalized.

  3. Research peptide route: Semaglutide and tirzepatide remain available from research peptide vendors with third-party COA testing. For current vendor pricing and stock, see semaglutide vendor comparison and tirzepatide vendor comparison.

For the broader context on GLP-1 compounding regulations, see our coverage of the FDA 503B exclusion proposal and the compounding pharmacy landscape.

CategoryWeight Loss & Metabolic Peptides
ClassGLP-1 agonist
GoalFat Loss
Best Kit Deal10-VialCOASave 36%

Ion Peptide — 100mg × 10 (1000mg) — $1493 $1269 with code thepeptidecatalog (15% off) ($1.27/mg)

Top Semaglutide Vendors

Ranked by price, COA availability, and reputation

1
Nura PeptideCOA
10/10
10mg$6.90/mg
2
Ascension PeptidesCOA
9.8/10
5mg$13.00/mg
3
Ion PeptideCOA
9.5/10
$3.45/mg
See full vendor rankings for Semaglutide →

Top Tirzepatide Vendors

Ranked by price, COA availability, and reputation

1
Nura PeptideCOA
10/10
$4.00/mg
2
Ascension PeptidesCOA
9.8/10
$7.47/mg
3
Ion PeptideCOA
9.5/10
$3.62/mg
See full vendor rankings for Tirzepatide →

How GLP-1s Reverse Liver Damage

The liver-specific mechanisms extend beyond weight loss:

  • Reduced hepatic de novo lipogenesis: GLP-1 receptor activation directly decreases the liver's production of new fat from carbohydrates
  • Lower lipid uptake: Tirzepatide specifically reduces CD36 and OBP2A expression — the transport proteins that shuttle fatty acids into hepatocytes
  • Anti-inflammatory effect: hsCRP drops 30-40% on GLP-1 therapy, exceeding what weight loss alone predicts. This blunts the inflammatory cascade that drives MASH progression from simple steatosis to fibrosis
  • Improved insulin sensitivity: Hepatic insulin resistance is the metabolic engine behind MASH. Both semaglutide and tirzepatide restore liver insulin signaling, reducing the downstream lipotoxicity

Two glowing vials — blue semaglutide and purple tirzepatide — with molecular pathway diagrams flowing toward a healing liver on dark navy background

The Bigger Picture: A $33 Billion Market

The global MASH treatment market reached $8.13 billion in 2025 and is projected to hit $33 billion by 2033. Until 2024, resmetirom was the only FDA-approved therapy. Adding two GLP-1 drugs in consecutive years — especially drugs that millions of patients already take for weight loss or diabetes — could accelerate diagnosis rates and treatment adoption dramatically.

For the cardiovascular protection data that further supports GLP-1 use in the metabolic syndrome population most likely to have MASH, the recent 91,490-patient meta-analysis showed a 13% MACE reduction class-wide.

30ml bacteriostatic water vial — 0.9% benzyl alcohol multi-dose
Bac Water Made for Peptides50% off
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
See why our bac water doesn't ruin peptides
Ships fast · 50% off with code thepeptidecatalog

Frequently Asked Questions

Are GLP-1 drugs FDA-approved for fatty liver disease?
Yes. Semaglutide received FDA approval for non-cirrhotic MASH with moderate-to-advanced fibrosis (stages F2-F3) in August 2025 based on the Phase 3 ESSENCE trial. Tirzepatide received FDA approval for MASH in early 2026 based on the Phase 2 SYNERGY-NASH trial and breakthrough therapy designation. Both are now available as on-label treatments for metabolic dysfunction-associated steatohepatitis.
Which GLP-1 works better for fatty liver — semaglutide or tirzepatide?
Both show strong MASH resolution rates. Semaglutide resolved steatohepatitis in 62.9% of patients at 72 weeks in the ESSENCE trial. Tirzepatide resolved MASH in up to 73.3% at 52 weeks in the SYNERGY-NASH trial. For fibrosis specifically, semaglutide has more mature Phase 3 data. The 2026 EASO guidelines position both for MASH resolution but list only semaglutide for fibrosis improvement based on current evidence.
How do GLP-1 drugs reverse fatty liver disease?
GLP-1 receptor agonists reduce liver fat through multiple mechanisms: they decrease hepatic de novo lipogenesis, reduce lipid uptake via CD36 and OBP2A pathways, lower systemic inflammation (hsCRP drops 30-40%), and improve insulin sensitivity. Weight loss accelerates these effects, but liver-specific mechanisms operate independently of body weight reduction — real-world data shows liver enzyme improvements even before significant weight loss occurs.
Can I get semaglutide or tirzepatide for liver disease from a compounding pharmacy?
503A compounding pharmacies can prepare semaglutide and tirzepatide with a valid prescription. The FDA's April 2026 proposal to exclude these from the 503B bulks list is in public comment through June 2026 but has not been finalized. Research-grade semaglutide and tirzepatide are also available from vetted peptide vendors with COA testing. See vendor comparisons at /best/semaglutide and /best/tirzepatide.
How long does it take for GLP-1 drugs to improve fatty liver?
Liver fat reduction begins within the first 12 weeks based on imaging data from ESSENCE and SYNERGY-NASH. Histological MASH resolution (confirmed by biopsy) was measured at 52 weeks in the SYNERGY-NASH trial and 72 weeks in ESSENCE. Liver enzyme normalization (ALT, AST) typically occurs within 24-36 weeks. Full fibrosis improvement requires longer treatment — the ESSENCE trial measured fibrosis endpoints at 72 weeks with continued improvement trending at longer follow-up.